Results of circulating miRs in ovarian cancer diagnosis
| Author | Year | Sample types | Upregulated | Downregulated | Tumor type | Control |
|---|---|---|---|---|---|---|
| Douglas D. Taylor | 2008 | Exosomal (Serum) miRNA | MiR-21, miR-141, miR-200a, MiR-200c, miR-200b, MiR-203, miR-205 miR-214 | aOPSC | Benign ovarian adenoma | |
| Kimberly E. Resnick | 2008 | Serum miRNA | MiR-21, miR-92, miR-93, MiR-126 miR-29a | MiR-155, miR-127 MiR-99b | bEOC | Healthy controls |
| SFM HÓ“usler | 2010 | Blood-derived miRNA | MiR-30c1 | MiR-342-3p, MiR-181a, MiR-450b-5p | 87.5% relapsed cSOC | Healthy controls |
| Casina WS Kan | 2012 | Serum miRNA | MiR-200a, miR-200b, MiR- 200c | cSOC (High-grade) | Healthy controls | |
| Ye-Won Chung | 2013 | Serum miRNA | MiR-132, miR-26a, Let-7b, miR-145 | cSOC | Healthy controls | |
| Swati Suryawanshi | 2013 | Plasma miRNA | MiR-16, miR-21, miR-191 | dEAOC | Healthy controls | |
| MiR-16, miR-191, miR-4284 | cSOC |
aOPSC, ovarian papillary serous cystadenocarcinoma; bEOC, epithelial ovarian cancer; cSOC, serous ovarian cancer; dEAOC, endometriosis-associated ovarian cancer.